CohBar, Inc. (CWBR)

MENLO PARK, Calif.--(BUSINESS WIRE)--On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a “public shell,” and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of CohBar, Inc. (the “Company”) (NasdaqCM: CWBR) with Morphogenesis, Inc. pursuant to which CohBar shareholders will end up owning approximately 15% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023.

MILWAUKEE, May 24, 2023 /PRNewswire/ — Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc. Click here to learn how to join the action https://www.ademilaw.com/case/cohbar-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. CohBar public stockholders […]...

CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of CohBar, Inc. (NASDAQ: CWBR) and Morphogenesis, Inc. is fair to CohBar shareholders. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether CohBar and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for CohBar shareholders; and (2) disclose all material information necessary for CohBar shareholders to adequately assess and value the merger consideration. On behalf of CohBar shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500.

A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.

MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022.

CohBar, Inc. (NASDAQ:CWBR ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is Ryan, and I will be your conference operator for today.

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.

CohBar Inc. (NASDAQ:CWBR ) Q1 2022 Results Conference Call May 16, 2022 5:00 PM ET Company Participants Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is John, and I will be your conference operator today.

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET